Zogenix, Inc. ZGNX 3.37% shares jumped another 5.6 percent Monday morning after exploding higher by 172 percent Sept. 29 in the wake of positive data on anti-epileptic drug ZX008. Shares of GW Pharmaceuticals PLC-ADR GWPH 0.31% plummeted 9.6 percent last Friday as well, and dropped another 2.3 percent Monday as investors see ZX008 as a potential threat to GW’s Epidiolex epilepsy treatment drug candidate.
According to Cantor Fitzgerald analyst Elemer Piros, those fears are ungrounded. In a recent note to clients, Piros said there is plenty of room in the market for more than one treatment for pediatric epilepsy.
“Our Epidiolex model estimates a peak market penetration of 33%, already anticipating share between other promising agents such as ZX008,” Piros said.
Piros said GW already enjoys a critical one-year lead in the battle for commercial market share. Zogenix is aggressively hoping to begin phase III trials by the end of the year.
Piros said over half of all epilepsy patients require multiple drug treatments to help control the condition, so GW investors should expect plenty of patient overlap with competitors such as Zogenix. In fact, as more competitors enter the market, combination therapies with Epidiolex will likely improve the efficacy and safety profile for patients, Piros wrote.
Piros said investors shouldn’t dismiss Epidiolex’s “outstanding” trial data, and Cantor Fitzgerald is not modifying its outlook for GW at all based on Zogenix’s results. The firm maintains…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
